medRxiv : the preprint server for health sciences · 2024
African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jerez Pilar Álvarez, Wild Crea Peter A, Ramos Daniel M, Gustavsson Emil K, Radefeldt Mandy, Makarious Mary B, Ojo Oluwadamilola O, Billingsley Kimberley J, Malik Laksh, Daida Kensuke, Bromberek Sarah, Hu Carol, Schneider Zachary, Surapaneni Aditya L, Stadler Julia, Rizig Mie, Morris Huw R, Pantazis Caroline B, Leonard Hampton L, Screven Laurel, Qi Yue A, Nalls Mike A, Bandres-Ciga Sara, Hardy John, Houlden Henry, Eng Celeste, Burchard Esteban González, Kachuri Linda, Global Parkinson’s Genetics Program (GP2), Singleton Andrew B, Fischer Steffen, Bauer Peter, Reed Xylena, Ryten Mina, Beetz Christian, Ward Michael, Okubadejo Njideka U, Blauwendraat Cornelis
Аннотация
Recently, a novel African ancestry specific Parkinson's disease (PD) risk signal was identified at the gene encoding glucocerebrosidase (GBA1). This variant (rs3115534-G) is carried by ~50% of West African PD cases and imparts a dose-dependent increase in risk for disease. The risk variant has varied frequencies across African ancestry groups, but is almost absent in European and Asian ancestry populations. GBA1 is a gene of high clinical and therapeutic interest. Damaging bi-allelic protein-coding variants cause Gaucher disease and mono-allelic variants confer risk for PD and Dementia with Lewy Bodies, likely by reducing the function of glucocerebrosidase. Interestingly, the novel African ancestry specific GBA1 risk variant is a non-coding variant, suggesting a different mechanism of action. Using full length RNA transcript sequencing, we identified intron 8 expression in risk variant carriers (G) but not in non-variant carriers (T). Antibodies targeting the N-terminus of glucocerebrosidase showed that this intron-retained isoform is likely not protein coding and subsequent proteomics did not identify a shorter protein isoform, suggesting the disease mechanism is RNA-based. CRISPR editing of the reported index variant (rs3115534) revealed that this is the responsible sequence alteration driving production of these intron 8 containing transcripts. Follow-up analysis of this variant showed that it is in a key intronic branchpoint sequence and therefore has important implications in splicing and disease. In addition, when measuring glucocerebrosidase activity we identified a dose-dependent reduction in risk variant carriers (G). Overall, we report the functional effect of a GBA1 non-coding risk variant, which acts by interfering with the splicing of functional GBA1 transcripts, resulting in reduced protein levels and reduced glucocerebrosidase activity. This understanding reveals a novel therapeutic target in an underserved and underrepresented population.